Completed PHASE2 INTERVENTIONAL 2-arm NCT03173560

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Sponsor: Eisai Inc.

Conditions Renal Cell Carcinoma

Interventions everolimus lenvatinib

Updated 30 times since 2017 Last updated: Mar 12, 2025 Started: Aug 17, 2017 Primary completion: Feb 14, 2020 Completion: Jun 20, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Renal Cell Carcinoma, this trial is completed. The trial is conducted by Eisai Inc. and has accumulated 30 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

30 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
May 2025 — Sep 2025 [monthly]

Completed PHASE2
Oct 2024 — May 2025 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2

▶ Show 25 earlier versions

Mar 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Oct 2023 — Mar 2024 [monthly]

Active Not Recruiting PHASE2
Apr 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE2
Nov 2022 — Apr 2023 [monthly]

Active Not Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE2
Jun 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE2
Nov 2021 — Jun 2022 [monthly]

Active Not Recruiting PHASE2
Jun 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE2
Apr 2021 — Jun 2021 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2
Jul 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE2
Jan 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
May 2019 — Jan 2020 [monthly]

Recruiting PHASE2
Apr 2019 — May 2019 [monthly]

Recruiting PHASE2
Dec 2018 — Apr 2019 [monthly]

Recruiting PHASE2
Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE2
Aug 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2018 — Mar 2018 [monthly]

Recruiting PHASE2
Dec 2017 — Jan 2018 [monthly]

Recruiting PHASE2
Nov 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Oct 2017 — Nov 2017 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2017 — Oct 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Inc.
Merck Sharp & Dohme LLC

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Arezzo, Italy , Athens, Greece , Badalona, Spain , Barcelona, Spain , Barnaul, Russia , Brno, Czechia , Brzozów, Poland , Calgary, Canada , Chelyabinsk, Russia and 64 more locations